EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Evolution of Clinical Indications for Mitral Valve Transcatheter Edge-to-Edge Repair

Carla Iglesias-Otero iD, Julio Echarte-Morales iD, David González-Fernández, Andrés Íñiguez-Romo, Rodrigo Estévez-Loureiro iD

Reviews in Cardiovascular Medicine · 23.03.2026 · 27 (3)

DOI: 10.31083/rcm47139 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Reviews in Cardiovascular Medicine, online erschienen am 23.03.2026. Verfasst von Carla Iglesias-Otero und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, University Hospital Alvaro Cunqueiro, 36312 Vigo, Spain. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mitral valve transcatheter edge-to-edge repair (M-TEER) has evolved from a highly specialized intervention to an essential treatment option for patients with severe mitral regurgitation (MR) who are unsuitable candidates for surgery. Moreover, current guidelines support the use of M-TEER in both secondary MR and selected cases of primary MR. In addition to these established indications, data from clinical trials and registries indicate that M-TEER is associated with improved short-term outcomes compared with conservative therapy in acute MR after myocardial infarction, and is beneficial in more complex scenarios, such as advanced heart failure, hypertrophic obstructive cardiomyopathy, and mitral annulus calcification. Meanwhile, combined strategies, such as repairing the mitral and tricuspid valves simultaneously, adding M-TEER to transcatheter aortic valve replacement, or performing this procedure alongside left atrial appendage closure, are gaining ground as practical ways to address the broader needs of these high-risk patients. More recently, M-TEER has been used in patients with moderate MR, as this stage is now recognized to be associated with adverse outcomes. Overall, current evidence supports M-TEER as a safe and versatile therapy across an expanding range of clinical scenarios. Nonetheless, ongoing studies will help further clarify long-term outcomes and refine patient selection.

Schlagwörter

Stichwörter der Autor:innen

acute mitral regurgitationexpanding indicationsheart failuremitral regurgitationmitral transcatheter edge-to-edge repair

Autor:innen und Institutionen

  • Department of Cardiology, University Hospital Alvaro Cunqueiro, 36312 Vigo, Spain.
  • Cardiovascular Research Group, Department of Cardiology, University Hospital Alvaro Cunqueiro, Fundación Biomédica Galicia Sur, Servizo Galego de Saude, University of Vigo, 36312 Vigo, Spain.

ORCID-Profile: Carla Iglesias-Otero, Julio Echarte-Morales, Rodrigo Estévez-Loureiro

Zitieren

APA

Iglesias-Otero, C., Echarte-Morales, J., González-Fernández, D., Íñiguez-Romo, A., & Estévez-Loureiro, R. (2026). Evolution of Clinical Indications for Mitral Valve Transcatheter Edge-to-Edge Repair. Reviews in Cardiovascular Medicine, 27(3). https://doi.org/10.31083/rcm47139

Vancouver

Iglesias-Otero C, Echarte-Morales J, González-Fernández D, Íñiguez-Romo A, Estévez-Loureiro R. Evolution of Clinical Indications for Mitral Valve Transcatheter Edge-to-Edge Repair. Reviews in Cardiovascular Medicine. 2026;27(3). doi:10.31083/rcm47139

BibTeX
@article{IglesiasOtero2026,
  author = {Iglesias-Otero, Carla and Echarte-Morales, Julio and González-Fernández, David and Íñiguez-Romo, Andrés and Estévez-Loureiro, Rodrigo},
  title = {Evolution of Clinical Indications for Mitral Valve Transcatheter Edge-to-Edge Repair},
  journal = {Reviews in Cardiovascular Medicine},
  year = {2026},
  volume = {27},
  number = {3},
  doi = {10.31083/rcm47139}
}
Kostenlos starten →